|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, we demonstrated that IL7 mediates an intrinsic and physiologic mechanism of GC resistance in normal thymocyte development that is retained during leukemogenesis in a subset of T-ALLs and is reversible with targeted inhibition of the IL7R/JAK/STAT5/BCL-2 axis.
|
31687977 |
2020 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
SIRT3 knockout attenuated B cell lymphomagenesis in VavP-Bcl2 mice without affecting normal GC formation.
|
31185214 |
2019 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This was associated with BRD4 eviction from genomic loci involved in leukemogenesis including BCL2 and MYC.
|
30568163 |
2018 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treatment of Ph+ ALL cells, including samples from relapsed/refractory patients, with the PIM kinase inhibitor AZD1208 and/or the BCL2 family antagonist Sabutoclax markedly suppressed cell growth and leukemogenesis <i>ex vivo</i> and in mice.
|
30154155 |
2018 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results suggest BCLW may be equally as important in lymphomagenesis as BCL2 and that targeting BCLW in lymphomas should be considered.<i></i>.
|
28855351 |
2017 |
|
Leukemogenesis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Chemical CHK1 inhibition induces BCL2-regulated apoptosis in primary as well as malignant B-cells and CHK1 expression levels control the timing of lymphomagenesis in mice.
|
29167438 |
2017 |
|
Leukemogenesis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The first such study by Limpens and colleagues on t(14/18)/ BCL2-JH [1] and next in line [2, 3] led to many questions regarding the significance of these chromosomal translocations in leukemogenesis.
|
27468869 |
2016 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since BCL2 family members have been proposed to play a role in leukemogenesis, we investigated combined effects of ETV6/RUNX1 with exogenous expression of the antiapoptotic protein BCL2 by crossing ETV6/RUNX1 transgenic animals with Vav-BCL2 transgenic mice.
|
26919255 |
2016 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Enteropathy was seen near the IEL zone in type II EATL, and activation of the c-Met, mitogen-activated protein kinase/extracellular signal-regulated kinase-mitogen-activated protein kinase pathway, and c-Myc-Bcl2-mediated cell survival may play important roles in lymphomagenesis, converting enteropathy to type II EATL.
|
24746558 |
2014 |
|
Leukemogenesis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This diversity captures a clonal hierarchy, resolved using immunoglobulin somatic mutations and IGH-BCL2 translocations as a frame of reference and by comparing diagnosis and relapse tumor pairs, allowing us to distinguish early versus late genetic eventsduring lymphomagenesis.
|
23297126 |
2013 |
|
Leukemogenesis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In siRNA experiments, DDX6 appeared not to be involved in NF-κB activation as frequently observed for genes promoting lymphomagenesis but was found to interfere with the expression of BCL6 and BCL2 in an NF-κB independent manner.
|
22965301 |
2013 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These studies show that the Igh 3' enhancers have an important role in the deregulation of Bcl2 and B-cell lymphomagenesis in vivo.
|
21606958 |
2011 |
|
Leukemogenesis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our results suggest that GATA1s may facilitate leukemogenesis and potentially impact therapeutic responses in DS AMkL by promoting proliferation and survival, and by repressing megakaryocytic lineage differentiation, potentially by regulating expression of Bcl-2 protein and other relevant genes.
|
22110660 |
2011 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data suggest that both Lmo2 and Bcl-2 are required for the action of E2A-HLF in leukemogenesis.
|
21072044 |
2011 |
|
Leukemogenesis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Recent studies have shown that miR-17-92 down-regulates the proapoptotic protein Bim, leading to overexpression of Bcl2, which likely plays a key role in lymphomagenesis.
|
18941111 |
2009 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results identify an important function for BCL6 in facilitating apoptosis of GC B cells via suppression of BCL2, and suggest that blocking this pathway is critical for lymphomagenesis.
|
19549844 |
2009 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using a mouse model of MYC-driven leukemia, we showed that, in addition to the well characterized BCL2 and BCLxl (BCL2L1), the other four family members -- BCLw (BCL2L2), BCLb (BCL2L10), BFL1 (BCL2A1) and MCL1 -- also cooperate with MYC to accelerate leukemogenesis.
|
19137012 |
2009 |
|
Leukemogenesis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This work therefore provides the first evidence that BHRF1, the EBV bcl2 homologue, is constitutively expressed as a latent protein in growth-transformed cells in vitro and, in the context of Wp-restricted BL, may contribute to virus-associated lymphomagenesis in vivo.
|
19283066 |
2009 |
|
Leukemogenesis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our results suggest that the ATM protein is more strongly correlated with PCNS DLBCL lymphomagenesis than with non-CNS DLBCLs, especially in germinal center B-cell-like subtypes demonstrating low Ki-67 labeling indexes and low Bcl-2 expression.
|
17516749 |
2007 |
|
Leukemogenesis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Even the low level of MYC, however, clearly affected T-cell cycling, size, and sensitivity to apoptosis, and coexpression of a BCL2 transgene promoted efficient T-cell lymphomagenesis.
|
16537801 |
2006 |
|
Leukemogenesis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A high frequency of BCL2 mRNA overexpression and a relatively low frequency of BAX mRNA overexpression detected in both analyzed leukemias in this study, indicate that altered transcription of these genes may be involved in leukemogenesis.
|
16059649 |
2005 |
|
Leukemogenesis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Enforced expression of the antiapoptotic Bcl-2 family protein Mcl-1 promotes lymphomagenesis in the mouse; however, the functional role of Mcl-1 in human B-cell lymphoma remains unclear.
|
15122313 |
2004 |
|
Leukemogenesis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Finally, these results provide additional evidence that BCL2-IGH translocation measurements could be a measure of acquired genetic instability in relation to genotoxic exposure in a gene directly relevant in term of lymphomagenesis.
|
15026372 |
2004 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have shown that Bcl-2, Akt, and the translational regulator eIF4E cooperate with Myc during lymphomagenesis and are potent inducers of drug resistance.
|
15190216 |
2004 |
|
Leukemogenesis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Although the t(14;18)-induced over-expression of BCL-2 is an important step in lymphomagenesis, this aberration alone is not sufficient to produce malignant lymphoma.
|
12169673 |
2002 |